Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

10.02.2022 | main topic

Natalizumab treatment during pregnancy in multiple sclerosis—clinical and bioethical aspects of an ongoing debate

verfasst von: Klaus Berek, Claudia Paganini, Harald Hegen, Gabriel Bsteh, Astrid Grams, Michael Auer, Thomas Berger, Florian Deisenhammer, MD, PhD Franziska Di Pauli

Erschienen in: Wiener Medizinische Wochenschrift

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

Natalizumab is an approved treatment for relapsing remitting multiple sclerosis; however, its safety during pregnancy is not formally proven.

Case presentation

We report a woman with multiple sclerosis being treated with natalizumab before pregnancy. After withdrawal of natalizumab, she suffered a severe, disabling rebound. In agreement with the patient, natalizumab was restarted during pregnancy. Our patient improved substantially and gave birth to a healthy boy.

Conclusion

Use of natalizumab during pregnancy may be an option in highly active multiple sclerosis.
Literatur
1.
Zurück zum Zitat Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–17. CrossRef Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–17. CrossRef
2.
Zurück zum Zitat Cree BAC, Mares J, Hartung HP. Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Curr Opin Neurol. 2019;32(3):365–77. CrossRef Cree BAC, Mares J, Hartung HP. Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Curr Opin Neurol. 2019;32(3):365–77. CrossRef
3.
Zurück zum Zitat Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910. CrossRef Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910. CrossRef
4.
Zurück zum Zitat Simone IL, Tortorella C, Ghirelli A. Influence of pregnancy in multiple sclerosis and impact of disease-modifying therapies. Front Neurol. 2021;12:697974. CrossRef Simone IL, Tortorella C, Ghirelli A. Influence of pregnancy in multiple sclerosis and impact of disease-modifying therapies. Front Neurol. 2021;12:697974. CrossRef
5.
Zurück zum Zitat Guger M, Traxler G, Drabauer M, Leitner-Pohn D, Enzinger C, Leutmezer F, et al. Pregnancy outcomes in patients with multiple sclerosis exposed to natalizumab‑A retrospective analysis from the Austrian multiple sclerosis treatment registry. Front Neurol. 2020;11:676. CrossRef Guger M, Traxler G, Drabauer M, Leitner-Pohn D, Enzinger C, Leutmezer F, et al. Pregnancy outcomes in patients with multiple sclerosis exposed to natalizumab‑A retrospective analysis from the Austrian multiple sclerosis treatment registry. Front Neurol. 2020;11:676. CrossRef
6.
Zurück zum Zitat Landi D, Marfia GA. Exposure to natalizumab during pregnancy and lactation is safe—Yes. Mult Scler. 2020;26(8):887–9. CrossRef Landi D, Marfia GA. Exposure to natalizumab during pregnancy and lactation is safe—Yes. Mult Scler. 2020;26(8):887–9. CrossRef
7.
Zurück zum Zitat Airas L. Exposure to natalizumab during pregnancy and lactation is safe—No. Mult Scler. 2020;26(8):889–91. CrossRef Airas L. Exposure to natalizumab during pregnancy and lactation is safe—No. Mult Scler. 2020;26(8):889–91. CrossRef
8.
Zurück zum Zitat Peng A, Qiu X, Zhang L, Zhu X, He S, Lai W, et al. Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review. J Neurol Sci. 2019;396:202–5. CrossRef Peng A, Qiu X, Zhang L, Zhu X, He S, Lai W, et al. Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review. J Neurol Sci. 2019;396:202–5. CrossRef
9.
Zurück zum Zitat Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. Neurology. 2018;90(10):e823–e31. CrossRef Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. Neurology. 2018;90(10):e823–e31. CrossRef
10.
Zurück zum Zitat Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. Neurology. 2018;90(10):e832–e9. CrossRef Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. Neurology. 2018;90(10):e832–e9. CrossRef
11.
Zurück zum Zitat Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol. 2016;16(1):150. CrossRef Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol. 2016;16(1):150. CrossRef
12.
Zurück zum Zitat Ebrahimi N, Herbstritt S, Gold R, Amezcua L, Koren G, Hellwig K. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler. 2015;21(2):198–205. CrossRef Ebrahimi N, Herbstritt S, Gold R, Amezcua L, Koren G, Hellwig K. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler. 2015;21(2):198–205. CrossRef
13.
Zurück zum Zitat Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T, Elias-Hamp B, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71(7):891–5. CrossRef Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T, Elias-Hamp B, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71(7):891–5. CrossRef
14.
Zurück zum Zitat Portaccio E, Ghezzi A, Hakiki B, Sturchio A, Martinelli V, Moiola L, et al. Postpartum relapses increase the risk of disability progression in multiple sclerosis: The role of disease modifying drugs. J Neurol Neurosurg Psychiatry. 2014;85(8):845–50. CrossRef Portaccio E, Ghezzi A, Hakiki B, Sturchio A, Martinelli V, Moiola L, et al. Postpartum relapses increase the risk of disability progression in multiple sclerosis: The role of disease modifying drugs. J Neurol Neurosurg Psychiatry. 2014;85(8):845–50. CrossRef
15.
Zurück zum Zitat Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2012;79(11):1130–5. CrossRef Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2012;79(11):1130–5. CrossRef
16.
Zurück zum Zitat Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011;17(8):958–63. CrossRef Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011;17(8):958–63. CrossRef
17.
Zurück zum Zitat Hellwig K, Brune N, Haghikia A, Müller T, Schimrigk S, Schwödiauer V, et al. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand. 2008;118(1):24–8. CrossRef Hellwig K, Brune N, Haghikia A, Müller T, Schimrigk S, Schwödiauer V, et al. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand. 2008;118(1):24–8. CrossRef
18.
Zurück zum Zitat De Las Heras V, De Andres C, Tellez N, Tintore M. Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy: a descriptive study in the Spanish population. Mult Scler. 2007;13(8):981–4. CrossRef De Las Heras V, De Andres C, Tellez N, Tintore M. Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy: a descriptive study in the Spanish population. Mult Scler. 2007;13(8):981–4. CrossRef
19.
Zurück zum Zitat Wehner NG, Shopp G, Oneda S, Clarke J. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol. 2009;86(2):117–30. CrossRef Wehner NG, Shopp G, Oneda S, Clarke J. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol. 2009;86(2):117–30. CrossRef
20.
Zurück zum Zitat Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord. 2019;12:1756286419837809. CrossRef Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord. 2019;12:1756286419837809. CrossRef
21.
Zurück zum Zitat Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol. 2014;261(6):1170–7. CrossRef Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol. 2014;261(6):1170–7. CrossRef
22.
Zurück zum Zitat Proschmann U, Thomas K, Thiel S, Hellwig K, Ziemssen T. Natalizumab during pregnancy and lactation. Mult Scler. 2018;24(12):1627–34. CrossRef Proschmann U, Thomas K, Thiel S, Hellwig K, Ziemssen T. Natalizumab during pregnancy and lactation. Mult Scler. 2018;24(12):1627–34. CrossRef
23.
Zurück zum Zitat Gonzalez-Suarez I, Rodriguez de Antonio L, Orviz A, Moreno-Garcia S, Valle-Arcos MD, Matias-Guiu JA, et al. Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation. Brain Behav. 2017;7(4):e671. CrossRef Gonzalez-Suarez I, Rodriguez de Antonio L, Orviz A, Moreno-Garcia S, Valle-Arcos MD, Matias-Guiu JA, et al. Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation. Brain Behav. 2017;7(4):e671. CrossRef
24.
Zurück zum Zitat Guilloton L, Pegat A, Defrance J, Quesnel L, Barral G, Drouet A. Neonatal pancytopenia in a child, born after maternal exposure to natalizumab throughout pregnancy. J Gynecol Obstet Hum Reprod. 2017;46(3):301–2. CrossRef Guilloton L, Pegat A, Defrance J, Quesnel L, Barral G, Drouet A. Neonatal pancytopenia in a child, born after maternal exposure to natalizumab throughout pregnancy. J Gynecol Obstet Hum Reprod. 2017;46(3):301–2. CrossRef
25.
Zurück zum Zitat Ciron J, Hautecoeur P, Mathis S, Neau J. Natalizumab throughout pregnancy: Risk of low platelet count in the newborn at delivery. Rev Neurol. 2015;172(2):165–6. CrossRef Ciron J, Hautecoeur P, Mathis S, Neau J. Natalizumab throughout pregnancy: Risk of low platelet count in the newborn at delivery. Rev Neurol. 2015;172(2):165–6. CrossRef
26.
Zurück zum Zitat De Giglio L, Gasperini C, Tortorella C, Trojano M, Pozzilli C. Natalizumab discontinuation and disease restart in pregnancy: a case series. Acta Neurol Scand. 2015;131(5):336–40. CrossRef De Giglio L, Gasperini C, Tortorella C, Trojano M, Pozzilli C. Natalizumab discontinuation and disease restart in pregnancy: a case series. Acta Neurol Scand. 2015;131(5):336–40. CrossRef
27.
Zurück zum Zitat O’Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76(22):1858–65. CrossRef O’Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76(22):1858–65. CrossRef
28.
Zurück zum Zitat Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis:‘Association of British Neurologists’ guidelines. Pract Neurol. 2019;19(2):106–14. CrossRef Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis:‘Association of British Neurologists’ guidelines. Pract Neurol. 2019;19(2):106–14. CrossRef
29.
Zurück zum Zitat Sandman L, Granger BB, Ekman I, Munthe C. Adherence, shared decision-making and patient autonomy. Med Health Care Philos. 2012;15(2):115–27. CrossRef Sandman L, Granger BB, Ekman I, Munthe C. Adherence, shared decision-making and patient autonomy. Med Health Care Philos. 2012;15(2):115–27. CrossRef
30.
Zurück zum Zitat Beauchamp TL, Childress JF. Principles of biomedical ethics. Oxford: Oxford University Press; 1979. Beauchamp TL, Childress JF. Principles of biomedical ethics. Oxford: Oxford University Press; 1979.
31.
Zurück zum Zitat Robertson L. Contemporary interpretation of informed consent: autonomy and paternalism. Br J Hosp Med (Lond). 2016;77(6):358–61. CrossRef Robertson L. Contemporary interpretation of informed consent: autonomy and paternalism. Br J Hosp Med (Lond). 2016;77(6):358–61. CrossRef
32.
Zurück zum Zitat Grady C. Enduring and emerging challenges of informed consent. N Engl J Med. 2015;372(9):855–62. CrossRef Grady C. Enduring and emerging challenges of informed consent. N Engl J Med. 2015;372(9):855–62. CrossRef
Metadaten
Titel
Natalizumab treatment during pregnancy in multiple sclerosis—clinical and bioethical aspects of an ongoing debate
verfasst von
Klaus Berek
Claudia Paganini
Harald Hegen
Gabriel Bsteh
Astrid Grams
Michael Auer
Thomas Berger
Florian Deisenhammer
MD, PhD Franziska Di Pauli
Publikationsdatum
10.02.2022
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-022-00913-6